CORDIS
EU research results

CORDIS

English EN

Anchored Muscle cELls for IncontinencE

Project information

Grant agreement ID: 874807

Status

Grant agreement signed

  • Start date

    1 September 2020

  • End date

    31 August 2025

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 9 526 097,25

  • EU contribution

    € 9 526 097,25

Coordinated by:

UNIVERSITY COLLEGE LONDON

United Kingdom

Objective

Faecal incontinence (FI) is a common condition affecting ~67 million people in Europe, seriously impairing living and productivity of affected individuals and their families. Women with FI arising from childbirth injury may benefit from regenerative medicine using autologous skeletal muscle derived cells (ASMDC) to restore function of damaged sphincter muscle. However, progress is hindered by sub-optimal manufacturing and delivery techniques contributing to inconsistent results. AMELIE proposes an innovative approach that uses ASMDC attached to implantable microcarriers that will enable delivery of a higher number of viable ASMDC into the damaged sphincter muscle, increasing the likelihood of cell engraftment, regeneration of muscle and improved continence. To achieve this, AMELIE will develop bespoke implantable microcarriers suitable for clinical use; establish robust bioprocessing for manufacture of the cell-microcarrier combination; and for the first time, robustly test, in a randomised clinical trial, the principle that delivery of ASMDC in an anchored, natural state, provides more effective and consistent treatment. AMELIE comprises a highly interdisciplinary, gender balanced, consortium of internationally recognised experts and key-opinion leaders with relevant experience from academia and industry across Europe in the fields of engineering (IST, PS, UCL, NHSBT), biological sciences (NHSBT, UCL, IISFJD), and translational regenerative medicine (QMUL, MUG, AUH, AU, RUH, UHE, IISFJD, CVBF). BCR will lead dissemination activity and stakeholder interaction with patients and the public, healthcare professionals, industry and third party FI charities across Europe to establish reciprocal dialogue with people that will interact with the new technology throughout the lifetime of the AMELIE project. TTOP will lead knowledge management and exploitation to develop a marketing strategy and business plan to facilitate future exploitation of the technology to ensure patient benefit.

Coordinator

UNIVERSITY COLLEGE LONDON

Address

Gower Street
Wc1e 6bt London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 4 488 266,11

Participants (12)

INSTITUTO SUPERIOR TECNICO

Portugal

EU Contribution

€ 452 360

QUEEN MARY UNIVERSITY OF LONDON

United Kingdom

EU Contribution

€ 1 129 739,53

MEDIZINISCHE UNIVERSITAT GRAZ

Austria

EU Contribution

€ 105 440

AARHUS UNIVERSITETSHOSPITAL

Denmark

EU Contribution

€ 88 005

AARHUS UNIVERSITET

Denmark

EU Contribution

€ 17 432,98

CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN

France

EU Contribution

€ 99 758,25

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 114 843,75

INSTITUTO INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ

Spain

EU Contribution

€ 345 775

NHS BLOOD AND TRANSPLANT

United Kingdom

EU Contribution

€ 1 374 064,13

TTOPSTART BV

Netherlands

EU Contribution

€ 180 750

BOWEL & CANCER RESEARCH

United Kingdom

EU Contribution

€ 331 775

CONSORZIO PER VALUTAZIONI BIOLOGICHE E FARMACOLOGICHE

Italy

EU Contribution

€ 797 887,50

Project information

Grant agreement ID: 874807

Status

Grant agreement signed

  • Start date

    1 September 2020

  • End date

    31 August 2025

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 9 526 097,25

  • EU contribution

    € 9 526 097,25

Coordinated by:

UNIVERSITY COLLEGE LONDON

United Kingdom